The Cambridge drugs company at the heart of an international take over row is warning that uncertainty over its future could interfere with vital research into life saving treatments.
There are fears that if Astrazeneca is scooped up by American company Pfeizer, its work won't get the right investment. Today Astrazeneca opened its doors to lay out its plans for growth in the region.
Today AstraZeneca was taking the story back to basics offering journalists a look behind the headlines and behind the scenes.
To see scientists working on the latest cancer treatment. The company says it has:
- 71 new drugs in the pipeline
- 10 of those are expected to come to market within the next ten years.
But if the American pharmaceutical company Pfizer is successful in taking-over the UK firm. There's concern from the scientists that life-saving treatments may be delayed. And innovation stifled.
Today AstraZeneca set out its stall. Cambridge central to its strategy.
With a £330m investment which will move the company's headquarters to the Cambridge Biomedical Campus, next to Addenbrooke's Hospital.
The firm also announced a collaboration with the Laboratory of Molecular Biology.